Genetics in lymphomagenesis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Next-generation sequencing (NGS) technologies have played an essential role in defining the somatic genomic landscape of lymphomas, with most characterized by a considerable heterogeneity and the lack of a pathognomonic genomic event. From the host perspective, there is strong evidence for familial aggregation across lymphoma subtypes, and this does not appear to be confounded by nongenetic factors, supporting a shared genetic etiology across subtypes. However, a family history of a specific lymphoma subtype is also generally most strongly associated with risk for that specific lymphoma, supporting etiologic heterogeneity. While no major genes have been identified for lymphomas, genome-wide association studies (GWAS) have identified over 60 common (minor allele frequency > 5%) risk loci, nearly all are associated with specific subtypes. Host genetics has long been hypothesized to influence treatment response, toxicity, and prognosis, but current studies are limited. Ongoing challenges in the “post-genomic” era relate to the functional validation of the large number of mutated genes in the tumor and GWAS loci in the germline, in order to dissect their role in lymphomagenesis. While the use of somatic and host genomics for precision diagnosis, treatment, and prevention remains very promising, additional discovery and translational research will be needed before widespread adoption in the clinic.

Original languageEnglish (US)
Title of host publicationNeoplastic Diseases of the Blood
PublisherSpringer International Publishing
Pages723-753
Number of pages31
ISBN (Electronic)9783319642635
ISBN (Print)9783319642628
DOIs
StatePublished - Jan 1 2018

Fingerprint

Lymphoma
Genome-Wide Association Study
Translational Medical Research
Genomics
Gene Frequency
Genes
Technology
Neoplasms

Keywords

  • Genome-wide association study
  • Genomics
  • Germline
  • Lymphoid leukemias
  • Lymphomas
  • Next-generation sequencing
  • Prognosis
  • Risk
  • Somatic

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cerhan, J. R., Braggio, E. D., Slager, S. L., & Novak, A. J. (2018). Genetics in lymphomagenesis. In Neoplastic Diseases of the Blood (pp. 723-753). Springer International Publishing. https://doi.org/10.1007/978-3-319-64263-5_38

Genetics in lymphomagenesis. / Cerhan, James R; Braggio, Esteban D; Slager, Susan L; Novak, Anne J.

Neoplastic Diseases of the Blood. Springer International Publishing, 2018. p. 723-753.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cerhan, JR, Braggio, ED, Slager, SL & Novak, AJ 2018, Genetics in lymphomagenesis. in Neoplastic Diseases of the Blood. Springer International Publishing, pp. 723-753. https://doi.org/10.1007/978-3-319-64263-5_38
Cerhan JR, Braggio ED, Slager SL, Novak AJ. Genetics in lymphomagenesis. In Neoplastic Diseases of the Blood. Springer International Publishing. 2018. p. 723-753 https://doi.org/10.1007/978-3-319-64263-5_38
Cerhan, James R ; Braggio, Esteban D ; Slager, Susan L ; Novak, Anne J. / Genetics in lymphomagenesis. Neoplastic Diseases of the Blood. Springer International Publishing, 2018. pp. 723-753
@inbook{b4cdecef11cc464b9ac026eaa528f118,
title = "Genetics in lymphomagenesis",
abstract = "Next-generation sequencing (NGS) technologies have played an essential role in defining the somatic genomic landscape of lymphomas, with most characterized by a considerable heterogeneity and the lack of a pathognomonic genomic event. From the host perspective, there is strong evidence for familial aggregation across lymphoma subtypes, and this does not appear to be confounded by nongenetic factors, supporting a shared genetic etiology across subtypes. However, a family history of a specific lymphoma subtype is also generally most strongly associated with risk for that specific lymphoma, supporting etiologic heterogeneity. While no major genes have been identified for lymphomas, genome-wide association studies (GWAS) have identified over 60 common (minor allele frequency > 5{\%}) risk loci, nearly all are associated with specific subtypes. Host genetics has long been hypothesized to influence treatment response, toxicity, and prognosis, but current studies are limited. Ongoing challenges in the “post-genomic” era relate to the functional validation of the large number of mutated genes in the tumor and GWAS loci in the germline, in order to dissect their role in lymphomagenesis. While the use of somatic and host genomics for precision diagnosis, treatment, and prevention remains very promising, additional discovery and translational research will be needed before widespread adoption in the clinic.",
keywords = "Genome-wide association study, Genomics, Germline, Lymphoid leukemias, Lymphomas, Next-generation sequencing, Prognosis, Risk, Somatic",
author = "Cerhan, {James R} and Braggio, {Esteban D} and Slager, {Susan L} and Novak, {Anne J}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-64263-5_38",
language = "English (US)",
isbn = "9783319642628",
pages = "723--753",
booktitle = "Neoplastic Diseases of the Blood",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Genetics in lymphomagenesis

AU - Cerhan, James R

AU - Braggio, Esteban D

AU - Slager, Susan L

AU - Novak, Anne J

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Next-generation sequencing (NGS) technologies have played an essential role in defining the somatic genomic landscape of lymphomas, with most characterized by a considerable heterogeneity and the lack of a pathognomonic genomic event. From the host perspective, there is strong evidence for familial aggregation across lymphoma subtypes, and this does not appear to be confounded by nongenetic factors, supporting a shared genetic etiology across subtypes. However, a family history of a specific lymphoma subtype is also generally most strongly associated with risk for that specific lymphoma, supporting etiologic heterogeneity. While no major genes have been identified for lymphomas, genome-wide association studies (GWAS) have identified over 60 common (minor allele frequency > 5%) risk loci, nearly all are associated with specific subtypes. Host genetics has long been hypothesized to influence treatment response, toxicity, and prognosis, but current studies are limited. Ongoing challenges in the “post-genomic” era relate to the functional validation of the large number of mutated genes in the tumor and GWAS loci in the germline, in order to dissect their role in lymphomagenesis. While the use of somatic and host genomics for precision diagnosis, treatment, and prevention remains very promising, additional discovery and translational research will be needed before widespread adoption in the clinic.

AB - Next-generation sequencing (NGS) technologies have played an essential role in defining the somatic genomic landscape of lymphomas, with most characterized by a considerable heterogeneity and the lack of a pathognomonic genomic event. From the host perspective, there is strong evidence for familial aggregation across lymphoma subtypes, and this does not appear to be confounded by nongenetic factors, supporting a shared genetic etiology across subtypes. However, a family history of a specific lymphoma subtype is also generally most strongly associated with risk for that specific lymphoma, supporting etiologic heterogeneity. While no major genes have been identified for lymphomas, genome-wide association studies (GWAS) have identified over 60 common (minor allele frequency > 5%) risk loci, nearly all are associated with specific subtypes. Host genetics has long been hypothesized to influence treatment response, toxicity, and prognosis, but current studies are limited. Ongoing challenges in the “post-genomic” era relate to the functional validation of the large number of mutated genes in the tumor and GWAS loci in the germline, in order to dissect their role in lymphomagenesis. While the use of somatic and host genomics for precision diagnosis, treatment, and prevention remains very promising, additional discovery and translational research will be needed before widespread adoption in the clinic.

KW - Genome-wide association study

KW - Genomics

KW - Germline

KW - Lymphoid leukemias

KW - Lymphomas

KW - Next-generation sequencing

KW - Prognosis

KW - Risk

KW - Somatic

UR - http://www.scopus.com/inward/record.url?scp=85047036500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047036500&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-64263-5_38

DO - 10.1007/978-3-319-64263-5_38

M3 - Chapter

AN - SCOPUS:85047036500

SN - 9783319642628

SP - 723

EP - 753

BT - Neoplastic Diseases of the Blood

PB - Springer International Publishing

ER -